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In-vitro evaluation of the quality of Paracetamol 
and Co-trimoxazole tablets used in Malawi based on 
pharmacopoeial standards
   Abstract
Objectives
This study was an in-vitro evaluation of  different brands of  paracetamol and 
cotrimoxazole tablets, used or found in Malawi, based on Pharmacopoeia 
standards, in order to ascertain the existence and extent of  substandard 
medicines in Malawi and to give an overview of  their distribution in the 
public and private sectors.
Methodology
A cross-sectional analytical study was conducted using 11 samples each 
of  paracetamol and cotrimoxazole tablets. Stratified random sampling 
was used to collect samples. Samples were analyzed using HPLC and 
Spectrophometric methods as outlined in the BP-2007 and USP-32 at the 
National Drug Quality Control Laboratory (NDQCL)-Lilongwe (under 
Pharmacy Medicines and Poisons Board-PMPB) and Orient Pharma Co. 
Ltd of  Taiwan. The results were analyzed using Epi Info.
Results and discussion
Fifty percent of  samples (n=22) were not registered in the country by the 
PMPB as required by the PMP Act with the majority of  those coming 
from public health facilities. All paracetamol and cotrimoxazole samples 
complied with identification tests using spectrophotometric and HPLC 
method. Overall, 27.3% of  samples failed to meet the BP-2007 standards 
for Active Ingredient content, while 22.7% of  the samples failed the 
Friability test. The results from Malawi are similar in magnitude to those 
within surrounding countries in Africa.
Conclusion 
This pilot study provides objective evidence to show that substandard 
and unregistered paracetamol and cotrimoxazole are present and being 
used in Malawi, and thus posing a considerable hazard to public health in 
Malawi. PMPB, together with the Ministry of  Health, must continue to 
develop a quality assurance system to ensure that medicines are randomly 
and routinely checked.
   Introduction
The Malawi Government through the Ministry of  Health 
and Pharmacy Medicines and Poisons Board (PMPB) 
adopted the Essential Drugs Concept in its National Drug 
Policy.1 The overall aim of  the policy is:  to contribute to 
the attainment of  quality health of  the Malawian population 
through equitable access to good quality, safe and efficacious 
drugs at affordable cost and rational use1. Malawi as a 
country has been focusing much of  its attention in the area 
of  rational drug use, while not much information is available 
concerning the quality of  the essential drugs on the Malawian 
market. 
A fundamental quality attribute for all pharmaceutical 
preparations is the requirement for constant dose of  drug 
between individual tablets. In practice, small variations 
between individual preparations are accepted and the 
limits for this variation are defined as standards in official 
pharmacopoeias like the British Pharmacopoeia (BP) or the 
United States of  America Pharmacopoeia (USP).2 There 
are several ways in which the quality of  medicines can be 
assessed (which can either be In-vitro or In-vivo). In-vitro 
methods are procedures employing test apparatus and 
equipment in testing medicines without involving laboratory 
animals or humans.2 In-vivo methods are more complex 
studies involving human subjects or laboratory animals 
mainly in assessing bioequivalence of  different brands.2 The 
in-vitro method is able to assess the impact of  the physical 
and chemical properties of  the drug, drug stability, and 
large-scale production of  the drug and drug product on the 
biologic performance of  the drug. 
If  a drug, upon laboratory testing in accordance with the 
specifications it claims to comply with, fails to meet the 
specifications, then it is classified as a substandard drug. 
Substandard drugs are drug products that do not meet quality 
specifications set for them and they may either be genuine 
or counterfeit medicinal products.3 The World Health 
Organization (WHO) defines a counterfeit medicine as “a 
medicine which is deliberately and fraudulently mislabeled 
with respect to identity and/or source3. Counterfeiting can 
apply to both branded and generic products and counterfeit 
products may include products with the correct ingredients 
or with the wrong ingredients, without active ingredients, 
with insufficient active ingredients or with fake packaging.”4 
There are several reports on the presence of  medicines or 
drugs of  doubtful quality (substandard medicines) on the 
market in both developed and developing countries.5-7
Consequences of  substandard medicines include: reduction 
in bioavailability as a result of  reduction in dissolution of  
active ingredient; the increasing drug-resistance among some 
of  the world’s most deadly infectious diseases, including 
malaria, tuberculosis and HIV/AIDS. The reason is that 
most counterfeit, substandard or degraded medicines contain 
incorrect levels of  a drug’s active ingredient, which causes 
the weaker strains of  the causal agent to be killed off  while 
allowing the drug-resistant strains to multiply and adapt.8 
The other consequence of  substandard drugs is the increase 
in cost of  treatment of  patients due to resistance as a result 
of  using substandard medicines. This increase in cost will 
directly affect government as it is the major funding agency 
for public health facilities in Malawi. The same increase in 
cost will be felt by the patients and their guardians in terms 
of  long stay in hospitals and in addition to direct payment in 
hospital fees. 
Data about substandard medicines, from other countries,5-7 
is available but there is lack of  available data on the 
Malawian market regarding the quality of  those medicines. 
The National Drug Quality Control Laboratory (NDQCL) 
(under PMPB) does routine testing of  drugs when they are 
to be registered in the country, but does not currently do 
post marketing testing and surveillance. A sample report 
of  the PMPB July 2006 to June 2007 showed that out of  
472 samples tested for the Central Medical Stores-Malawi, 
14 samples failed the test. Out of  213 products for which 
registration in Malawi was sought, 4 products failed the 
test.9 Overall 3% of  the products failed the test, and this 
represents only those drugs for government health facilities, 
while the majority of  drugs entering the country are not 
tested. As such much information of  substandard medicines 
in Malawi is not available. As such there is a lack of  adequate 
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data to ascertain the existence and extent of  substandard 
drugs in Malawi. Thus their use may result in reduction in 
bioavailability and an increase in drug-resistance to such 
drugs on the market. 
The study was aimed at providing detailed information on 
the quality (that is: active drug content, in-vitro availability-
disintegration and dissolution, and friability) of  paracetamol 
and co-trimoxazole available as tablet formulations on the 
Malawian market. Paracetamol and co-trimoxazole are 
essential drugs and the Ministry of  Health (Malawi) has 
listed them as vital drugs in the Malawi Standard Essential 
Medicines List, which must be available at all times from 
Health Centre level to Central Hospital level. Thus, the study 
aimed at establishing the existence of  substandard medicines 
on the Malawian market; serve as a guide for future studies 
to quantify the extent of  the problem in Malawi; and help 
policy makers regulate the availability of  the substandard 
medicines or drugs.
Materials and Methodology
This was a cross-sectional analytical study conducted in 
Blantyre, at the College of  Medicine with laboratory analysis 
of  the drugs conducted in Lilongwe at PMPB’s National 
Drug Quality Control Laboratory and afterwards sent to 
Orient Pharma in Taiwan for Dissolution Test and HPLC 
analysis. 
The drugs were sampled from various Government Health 
Facilities, Private or Retail pharmacies, Illegal Drug vendors, 
and ordinary groceries or shops using a multi-stage stratified 
random sampling. The country was divided into three 
regions and in each region one district was selected. In each 
selected district samples were collected from randomly 
selected public and private sector health providers. Table 
1 shows the detailed information on the samples that were 
assayed. A total of  11 different brands of  paracetamol and 
11 different brands of  Cotrimoxazole tablets were assayed, 
making a combined total of  22.
The drugs were anonymously purchased (or randomly 
selected in public health facilities) in their original package 
as supplied by the manufacturers, and only one package 
of  a particular brand was bought from any selected retail 
Pharmacy. All formulations sampled had a remaining stated 
shelf  life of  at least 1 year at the time of  sampling. All the 
samples were coded and manufacturer’s identity has been 
excluded for ethical reasons. 
Checking of  registration status was done by checking the 
label of  the bottle and also by looking at the registration 
status from the PMPB’s Registered List of  Products. 
Laboratory technicians from PMPB’s National Drug 
Quality control Laboratory helped the Investigator in the 
initial pharmaceutical analysis in Malawi and Laboratory 
technicians/technologists of  Orient Pharma company under 
the guidance of  Professor David H.W. Cheng of  Taipei 
Medical University did the final part of  the analysis (which 
included dissolution, HPLC analysis and validation of  the 
procedures) in Taiwan. 
Pure Paracetamol and Sulphamethoxazole and Trimethoprim 
standards were provided by the PMPB-Malawi and Orient 
Pharma in Taiwan. All reagents used during drug assay were 
of  HPLC grade. 
All drugs were assayed for the drug content immediately 
after purchase. The tested tablets were randomly selected 
from packages of  the same batch. The assays were repeated 
three times and the results presented are the mean of  three 
determinations. All drugs were assayed according to methods 
outlined in the individual drug monographs of  the British 
Pharmacopoeia 2007, except for Dissolution method which 
used United States Pharmacopoeia-32.
Data and Statistical analysis
Microsoft Windows Excel 2003 and Epi Info were used in 
the data entry and analysis respectively. Analysis of  variance 
(ANOVA) was used to compare the results between Public 
Health Facilities, Private Pharmacies and Illegal Vendors 
with  95% confidence interval (thus p=0.05).
Results
On registration of  samples, it was found out that 50% (n=22) 
of  the samples were not registered as of  30th June 2009 (six 
paracetamol samples and five co-trimoxazole samples) by 
the PMPB as required by the law, with public health facilities 
having 72.7% (n=11) of  samples not registered as compared 
to 28.57% (n=8) for private pharmacies and 33.3% (n=3) for 
Illegal vendors.
Also, all paracetamol and Cotrimoxazole (Sulfamethoxazole 
and Trimethoprim) tablets complied with identification of  
active ingredient as outlined in the BP 2007 and USP 32.
On individual tablet weight uniformity, only one product 
failed to meet the required standard, representing 5% 
(n=22). ANOVA analysis of  Uniformity of  Tablet Weight 
of  samples did not show a significant difference (p=0.001) 
between public health facilities, private pharmacies and 
Illegal vendors.
The content of  paracetamol active ingredient in the samples 
ranged from 94.57 to 98%, thus some falling short of  the 
acceptance limit for paracetamol of  95-105% in the BP. Ten 
paracetamol tablet brands met the required standard with 
only one paracetamol tablet formulation failing to meet the 
standard of  content of  active ingredient, thus representing 
9.1% of  paracetamol samples. 
The content of  sulfamethoxazole in the samples ranged 
from 91.04-107.3%, while that of  Trimethoprim was 65.57–
110.13%. The acceptance range for both sulfamethoxazole 
and Trimethoprim in BP 2007 is 92.5-107.5%. Five co-
trimoxazole brands failed to meet the required standards 
thus representing 45.5% of  co-trimoxazole samples, with 
one of  the brand having too much Trimethoprim content 
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(110.13%).
Combination of  paracetamol and cotrimoxazole samples 
showed that six tablet formulations failed to meet the 
BP 2007 standards of  Active Ingredient content, thus 
representing 27.3%.
The results of  active ingredient based on sources of  drugs 
showed that 27.3% (n=11) samples from public health 
facilities did not meet the required standard, while for private 
pharmacies and illegal vendors it was 25% (n=8) and 33.3% 
(n=3), see figure 1 below. The differences in failure rate based 
on source of  drugs was not statistically significant (p=0.001).
Figure 1: Results of  content of  active ingredient based on 
Type of  Facility 
All paracetamol and cotrimoxazole brands complied with 
the Disintegration test.
Only one formulation failed to meet the BP 2007 or USP-32 
requirements for Dissolution test, which is a release of  more 
than 80% of  paracetamol within 30 min and more than 70% 
for cotrimoxazole.
A product passes Friability Test if  the friability percent loss 
is less than 1%. There were three paracetamol preparations 
and two co-trimoxazole preparations which failed the test. 
On friability, 22.7% (n=22) of  all tablet formulations failed 
the test, all of  them were from public health facilities. 
ANOVA analysis of  Friability of  samples showed a 
significant difference (p=0.001) in the Friability failure rate. 
Public health facilities had a failure rate of  45.5% (n=11) of  
samples while private pharmacies and Illegal vendors did not 
have any friability failure.
Discussion
From the study, it had been observed that half  of  the 
sampled products were not registered with PMPB in Malawi 
with the MOH appearing to be the biggest source of  the 
problem. This may be due to laxity by the Central Medical 
Stores staff  when tendering or purchasing medicines for 
the public sector. Donors influence could also have been 
a contributing factor to this, since majority of  donors put 
strict restrictions on where to buy the medicines when 
using their funds, as such CMS and MOH may be forced 
to procure unregistered medicines. While inadequate human 
resource at the PMPB may have contributed to some of  
unregistered drugs which were found by illegal vendors and 
private Pharmacies. Registration of  Medicines in a country 
is a major pre-requisite before the medicine can be used 
by the general population. Registration ensures that the 
medicines have been thoroughly checked in terms to safety, 
quality and efficacy. A study conducted by Prazuck. T et al. 
in Northern Myanmar found out that 14.3% of  the samples 
(n=21) displayed the official registration number/label10 
while in this study, none of  the products had its registration 
number displayed. If  the maintenance of  a healthy nation is 
to be achieved then Registration of  medicines by PMPB is 
an important process which should not be ignored. By not 
displaying the registration number on the label, it becomes 
difficult for an ordinary consumer of  the medicines or the 
health professionals to know if  the product they are buying 
is an original or substandard or even counterfeit. 
A fundamental quality attribute for all pharmaceutical 
preparations is the requirement for constant dose of  drug 
between individual tablets. In practice, small variations 
between individual preparations are accepted and the 
limits for this variation are defined as standards in official 
pharmacopoeias like the BP and USP11,12. This study 
has demonstrated high overall failure rates for content 
uniformity of  the Co-trimoxazole and Paracetamol tablets at 
27.3% (n=22). Several studies have reported on low content 
of  active ingredient. Gaudiano, M. et al. (2007) reported one 
sample as having low quantity of  active ingredient in a study 
carried out in Congo, Burundi and Angola13. Ogwal-Okeng et 
al. found that 39% of  chloroquine in Uganda failed the active 
ingredient content test with 11 % having sub-normal and 28 
% having supranormal amounts.14 Kibwage et al. reported 
that about 45% of  drugs sampled on the Kenyan market and 
analysed at the Daru quality control laboratory on a routine 
basis were of  substandard quality in terms of  the content 
of  the active ingredient.15 Shakoor et al. reported both fake 
and substandard drugs on Thai and Nigerian markets where 
36.5% of  89 samples failed in the assay determination.6 In a 
study conducted by Prazuck et al. in Myanmar, it was found 
out that 33% (n=21) did not contain the stated dosage (one 
more than stated dosage and six less than stated dosage), and 
the highest deficit observed was 48% in two products (co-
trimoxazole and benzylpenicillin).10 And thus for Malawi, the 
extent of  the problem is within those found in other studies 
both in Africa and Asia.
The high failure of  Co-trimoxazole in this is a worrisome 
development considering that it is an antibiotic of  choice 
in most of  the infections prevalent in Malawi. Of  more 
importance to note is that in most cases Cotrimoxazole is 
indicated for prophylaxis for people living with HIV/AIDS, 
and the use of  substandard medication will just aggravate the 
problem instead of  solving it. The clinical use of  medicine 
preparations containing less than the optimum amount of  the 
active ingredient may be contributing to the poor treatment 
outcomes reported in Malawi. This may be another reason 
why a 2001 study by Zachariah et.al in Thyolo District of  
Malawi showed that co-trimoxazole resistance in E.coli 
among TB patients had significantly increased in a 2-year 
period in the district, though in that study resistance was 
apparently attributed to widespread availability.16 In 2006, a 
substandard or counterfeit pharmaceutical excipient caused 
more than 100 deaths in Panama.17 
From the results of  friability, 22.7% (5) of  all tablet 
formulations failed the test; all of  them were from public 
health facilities. Very few studies have been done on friability, 
though this may contribute to a greater loss of  drugs in most 
African countries. The failure of  the samples in the Friability 
indicates poor manufacturing of  the tablets rather than 
storage conditions of  the tablets. The results of  friability are 
a worrisome development in Malawi as all of  the drugs were 
from public health facilities. This is so because the majority 
of  health facilities in Malawi are in rural areas where the road 
network is poor and characterized by bumpy and un-tarred 
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(earth) roads, which makes the distribution of  those drugs 
to those remote health facilities a challenge. As a result many 
medicines which are dispatched to those health facilities may 
be wasted as a result of  friability or breakage, thus having a 
strain on drug budget expenditures.
Conclusions 
This pilot study provides objective evidence to show that 
substandard and unregistered paracetamol and cotrimoxazole 
are present and being used in Malawi, possibly posing a 
considerable hazard to health. PMPB, together with the 
Ministry of  Health, should develop a quality assurance 
system to ensure that medicines are randomly and routinely 
checked (post-marketing surveillance). 
There is a need for a large scale study of  different medicines 
found in Malawi to properly quantify the extent of  the 
problem. Prospective cohort studies need to be undertaken 
in order to assess the effects of  storage and transportation 
on the quality of  medicines in Malawi 
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